Halozyme Therapeutics ends collaboration agreement with Abzena
AIM-listed life sciences group Abzena said on Monday that its collaboration and licence agreement with Halozyme Therapeutics relating to the use of its ThioBridge linker technology for the development of antibody drug conjugate products has been terminated.
Abzena
15.75p
16:24 11/10/18
0.00%
0.00p
FTSE AIM All-Share
729.38
16:54 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
Under the agreement, Nasdaq-listed Halozyme had progressed the development of HTI-1511, an anti-epidermal growth factor receptor antibody drug conjugate product.
Pre-clinical results from this programme were presented at the 2017 meeting of the American Association for Cancer Research reporting the significant activity of HTI-1511 against multiple tumour types and a safety profile suitable for candidate nomination.
At 1550 BST, the shares were down 12.5% to 21p.